Picture of Verona Pharma logo

VRNA — Verona Pharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+5.58%
3m-29.25%
6m-13.53%
1yr-34.59%
Volume Change (%)
10d/3m+77.06%
Price vs... (%)
52w High-52.22%
50d MA-15.54%
200d MA-29.21%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-57.47%
Return on Equity-39.58%
Operating Margin-188.81%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Verona Pharma EPS forecast chart

Profile Summary

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The Company is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). It is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    March 31st, 2022
    Incorporated
    February 24th, 2005
    Public Since
    March 30th, 2005
    No. of Employees
    24
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    482,944,390

    VRNA Share Price Performance

    Upcoming Events for VRNA

    Verona Pharma PLC at H C Wainwright Global Investment Conference (Virtual)

    Similar to VRNA

    Picture of 4d Pharma logo

    4d Pharma

    us flag iconNASDAQ Global Market

    Picture of 89bio logo

    89bio

    us flag iconNASDAQ Global Market

    Picture of AcelRx Pharmaceuticals logo

    AcelRx Pharmaceuticals

    us flag iconNASDAQ Global Market

    Picture of AC Immune SA logo

    AC Immune SA

    us flag iconNASDAQ Global Market

    Picture of Adagene logo

    Adagene

    us flag iconNASDAQ Global Market

    FAQ

    Or unlock with your email

    Or unlock with your email